Table: Santen Pharm -6-MTH group results (IFRS)

SANTEN PHARMACEUTICAL

01/11/2017 06:00

Nov 1 (Reuters)-  
              Santen Pharmaceutical Co Ltd  
              CONSOLIDATED FINANCIAL HIGHLIGHTS  
     (in billions of yen unless specified)  
                   6 months ended      6 months ended       Year to  
                  Sep 30, 2017        Sep 30, 2016     Mar 31, 2018  
                     LATEST             YEAR-AGO          COMPANY    
                     RESULTS             RESULT          FORECAST    
  Sales              110.77               97.83           218.00     
                   (+13.2 pct)         (+0.0 pct)       (+9.5 pct)   
  Operating           21.04               18.79            37.40     
                   (+12.0 pct)         (-71.3 pct)      (+15.2 pct)  
  Pretax              20.69               16.88            37.70     
                   (+22.5 pct)         (-74.2 pct)      (+25.4 pct)  
  Net                 15.26               12.51            26.90     
                   (+22.0 pct)         (-71.4 pct)      (+23.8 pct)  
  EPS Basic         37.56 yen           30.21 yen        66.23 yen   
  EPS Diluted       37.42 yen           30.09 yen                    
  Ann Div                               26.00 yen        26.00 yen   
  -Q2 Div           13.00 yen           13.00 yen                    
  -Q4 Div                               13.00 yen        13.00 yen   
  
  NOTE - Santen Pharmaceutical Co Ltd.  
  (Figures are reported based on international accounting rules (IFRS).)  
  If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half  
  dividend and Q4 to the second-half dividend announced before a new corporate law in  
  2006 allowed companies to pay and report dividends on a quarterly basis. 
  *Net - represents Net profit attributable to owners of the parent company.  
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4536.T 
  ((Tokyo Headline News Desk +813 6441 1812))